سوق أمراض الكلى المزمنة العالمي - اتجاهات الصناعة والتوقعات حتى عام 2030

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 EPIDEMIOLOGY MODELING

2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER'S 5 FORCES

4.2 PESTEL ANALYSIS

5 INDUSTRY INSIGHTS

5.1 PATENT ANALYSIS

5.1.1 PATENT LANDSCAPE

5.1.2 USPTO NUMBER

5.1.3 PATENT EXPIRY

5.1.4 EPIO NUMBER

5.1.5 PATENT STRENGTH AND QUALITY

5.1.6 PATENT CLAIMS

5.1.7 PATENT CITATIONS

5.1.8 PATENT LITIGATION AND LICENSING

5.1.9 FILE OF PATENT

5.1.10 PATENT RECEIVED CONTRIES

5.1.11 TECHNOLOGY BACKGROUND

5.2 DRUG TREATMENT RATE BY MATURED MARKETS

5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

5.4 PATIENT FLOW DIAGRAM

5.5 KEY PRICING STRATEGIES

5.6 KEY PATIENT ENROLLMENT STRATEGIES

5.7 INTERVIEWS WITH SPECIALIST

5.8 OTHER KOL SNAPSHOTS

6 EPIDEMOLOGY

6.1 INCIDENCE RATE

6.2 TREATMENT RATE

6.3 MORTALITY RATE

6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

6.5 PATIENT TREATMENT SUCCESS RATES

7 MERGERS AND ACQUISITION

7.1 LICENSING

7.2 COMMERCIALIZATION AGREEMENTS

8 REGULATORY FRAMEWORK

8.1 REGULATORY APPROVAL PROCESS

8.2 GEOGRAPHIES' EASE OF REGULATORY APPROVAL

8.3 REGULATORY APPROVAL PATHWAYS

8.4 LICENSING AND REGISTRATION

8.5 POST-MARKETING SURVEILLANCE

8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES

9 PIPELINE ANALYSIS

9.1 CLINICAL TRIALS AND PHASE ANALYSIS

9.2 DRUG THERAPY PIPELINE

9.3 PHASE III CANDIDATES

9.4 PHASE II CANDIDATES

9.5 PHASE I CANDIDATES

9.6 OTHERS (PRE-CLINICAL AND RESEARCH)

TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR XX

Company Name Therapeutic Area

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE

Phase Number of Projects

Preclinical/Research Projects XX

Clinical Development XX

Phase I XX

Phase II XX

Phase III XX

U.S. Filed/Approved But Not Yet Marketed XX

Total XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE

Therapeutic Area Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE

Technology Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

10 MARKETED DRUG ANALYSIS

10.1 DRUG

10.1.1 BRAND NAME

10.1.2 GENERICS NAME

10.2 THERAPEUTIC INDIACTION

10.3 PHARACOLOGICAL CLASS OD THE DRUG

10.4 DRUG PRIMARY INDICATION

10.5 MARKET STATUS

10.6 MEDICATION TYPE

10.7 DRUG DOSAGES FORM

10.8 DOSAGES AVAILABILITY

10.9 PACKAGING TYPE

10.1 DRUG ROUTE OF ADMINISTRATION

10.11 DOSING FREQUENCY

10.12 DRUG INSIGHT

10.13 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.

10.13.1 FORECAST MARKET OUTLOOK

10.13.2 CROSS COMPETITION

10.13.3 THERAPEUTIC PORTFOLIO

10.14 CURRENT DEVELOPMENT SCENARIO

11 MARKET OVERVIEW

11.1 DRIVERS

11.2 RESTRAINS

11.3 OPPURTUNITY

11.4 CHALLENGES

12 MARKET ACCESS

12.1 10-YEAR MARKET FORECAST

12.2 CLINICAL TRIAL RECENT UPDATES

12.3 ANNUAL NEW FDA APPROVED DRUGS

12.4 DRUGS MANUFACTURER AND DEALS

12.5 MAJOR DRUG UPTAKE

12.6 CURRENT TREATMENT PRACTICES

12.7 IMPACT OF UPCOMING THERAPY

13 R & D ANALYSIS

13.1 COMPARATIVE ANALYSIS

13.2 DRUG DEVELOPMENTAL LANDSCAPE

13.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES

13.4 THERAPEUTIC ASSESSMENT

13.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS

14 GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET, BY DIAGNOSIS AND TREATMENT

(NOTE: MARKET VALUE, VOLUME AND ASP ANALYSIS WOULD BE PROVIDED FOR ALL SEGMENTS AND SUB-SEGMENTS OF PRODUCT)

14.1 OVERVIEW

14.2 DIAGNOSIS

14.2.1 BLOOD TESTS

14.2.1.1. CREATININE

14.2.1.2. OTHER BIOMARKERS

14.2.2 URINE TESTS

14.2.2.1. DIPSTICK TEST FOR ALBUMIN

14.2.2.2. URINE ALBUMIN-TO-CREATININE RATIO (UACR)

14.2.3 IMAGING TESTS

14.2.3.1. X-RAYS

14.2.3.2. PYELOGRAPHY

14.2.3.3. ULTRASONOGRAPHY

14.2.3.4. COMPUTED TOMOGRAPHY

14.2.3.5. OTHERS

14.2.4 BIOPSY

14.2.4.1. OPEN KIDNEY BIOPSY

14.2.4.2. PERCUTANEOUS KIDNEY BIOPSY

14.2.4.3. LAPAROSCOPIC KIDNEY BIOPSY

14.2.4.4. TRANSJUGULAR KIDNEY BIOPSY

14.3 TREATMENT

14.3.1 MEDICATION

14.3.1.1. MEDICATION, BY TYPE

14.3.1.1.1. SGLT2 INHIBITORS

14.3.1.1.1.1 DAPAGLIFLOZIN

14.3.1.1.1.2 OTHERS

14.3.1.1.2. ACE INHIBITORS

14.3.1.1.2.1 BENAZEPRIL

14.3.1.1.2.2 CAPTOPRIL

14.3.1.1.2.3 ENALAPRIL

14.3.1.1.2.4 CAPTOPRIL

14.3.1.1.2.5 LISINOPRIL

14.3.1.1.2.6 CAPTOPRIL

14.3.1.1.2.7 CAPTOPRIL

14.3.1.1.2.8 OTHERS

14.3.1.1.3. BETA BLOCKERS

14.3.1.1.3.1 ACEBUTOLOL

14.3.1.1.3.2 ATENOLOL

14.3.1.1.3.3 BISOPROLOL

14.3.1.1.3.4 NADOLOL

14.3.1.1.4. NADOLOL

14.3.1.1.4.1 AMILORIDE

14.3.1.1.4.2 BUMETANIDE

14.3.1.1.4.3 FUROSEMIDE

14.3.1.1.4.4 METOLAZONE

14.3.1.1.4.5 SPIRONOLACTONE

14.3.1.1.4.6 THIAZIDES

14.3.1.1.4.7 TORSEMIDE

14.3.1.1.4.8 TRIAMTERENE

14.3.1.1.5. ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)

14.3.1.1.5.1 EPOETIN ALFA

14.3.1.1.5.2 EPOETIN BETA

14.3.1.1.5.3 DARBEPOETIN ALFA

14.3.1.1.5.4 OTHERS

14.3.1.1.6. ANTIBIOTICS

14.3.1.1.6.1 CEFTRIAXONE

14.3.1.1.6.2 CLINDAMYCIN

14.3.1.1.6.3 DOXYCYCLINE

14.3.1.1.6.4 MOXIFLOXACIN

14.3.1.1.6.5 AZITHROMYCIN

14.3.1.1.6.6 CIPROFLOXACIN

14.3.1.1.6.7 LEVOFLOXACIN

14.3.1.1.6.8 OTHERS

14.3.1.1.7. DIURETICS

14.3.1.1.8. PHOSPHATE BINDERS

14.3.1.1.9. OTHERS

14.3.1.2. MEDICATION, BY ROUTE OF ADMINISTRATION

14.3.1.2.1. ORAL

14.3.1.2.1.1 TABLETS

14.3.1.2.1.2 CAPSULES

14.3.1.2.2. PARENTERAL

14.3.1.2.2.1 INTRAVENOUS

14.3.1.2.2.2 SUBCUTANEOUS

14.3.1.2.2.3 OTHER

14.3.1.2.3. OTHERS

14.3.1.3. MEDICATION, BY PRODUCT TYPE

14.3.1.3.1. BRANDED/ REFERENCE DRUG

14.3.1.3.1.1 KARENDIA

14.3.1.3.1.2 CAPOTEN

14.3.1.3.1.3 PRINIVIL

14.3.1.3.1.4 DAPRUDUSTAT

14.3.1.3.1.5 DIOVAN

14.3.1.3.1.6 SECTRAL

14.3.1.3.1.7 JARDIANCE

14.3.1.3.1.8 BYSTOLIC

14.3.1.3.1.9 COREG

14.3.1.3.1.10 CRESTOR

14.3.1.3.1.11 FARXIGA

14.3.1.3.1.12 OTHERS

14.3.1.3.2. GENERIC/ BIOSIMILAR DRUG

14.3.1.3.2.1 QUINAPRIL

14.3.1.3.2.2 CANDESARTAN

14.3.1.3.2.3 NEBIVOLOL

14.3.1.3.2.4 ROSUVASTATIN

14.3.1.3.2.5 OTHERS

14.3.1.4. MEDICATION, BY PRESCRIPTION TYPE

14.3.1.4.1. PRESCRIPTION DRUG

14.3.1.4.2. OTC DRUG

14.3.2 DIALYSIS

14.3.2.1. HEMODIALYSIS

14.3.2.1.1. CENTER-USE HEMODIALYSIS

14.3.2.1.2. HOME-USE HEMODIALYSIS

14.3.2.2. PERITONEAL DIALYSIS

14.3.2.2.1. CENTER-USE HEMODIALYSIS

14.3.2.2.2. HOME-USE HEMODIALYSIS

14.3.3 KIDNEY TRANSPLANTATION

14.3.3.1. DECEASED-DONOR KIDNEY TRANSPLANTS

14.3.3.2. LIVING-DONOR KIDNEY TRANSPLANTS

15 GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET, BY STAGE

15.1 OVERVIEW

15.2 STAGE 1

15.2.1 DIAGNOSIS

15.2.2 TREATMENT

15.3 STAGE 2

15.3.1 DIAGNOSIS

15.3.2 TREATMENT

15.4 STAGE 3

15.4.1 DIAGNOSIS

15.4.2 TREATMENT

15.5 STAGE 4

15.5.1 DIAGNOSIS

15.5.2 TREATMENT

15.6 STAGE 5

15.6.1 DIAGNOSIS

15.6.2 TREATMENT

16 GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET, BY AGE GROUP

16.1 OVERVIEW

16.2 PEDIATRIC

16.3 ADULT

16.4 GERIATRIC

17 GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET, BY GENDER

17.1 OVERVIEW

17.2 MALE

17.3 FEMALE

18 GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET, BY END USER

18.1 OVERVIEW

18.2 HOSPITALS

18.2.1 PRIVATE

18.2.1.1. TIER 1

18.2.1.2. TIER 2

18.2.1.3. TIER 3

18.2.2 PUBLIC

18.2.2.1. TIER 1

18.2.2.2. TIER 2

18.2.2.3. TIER 3CLINICS

18.3 DIAGNOSTIC CENTERS

18.4 DIALYSIS CENTERS

18.5 HOMECARE SETTINGS

18.6 OTHERS

19 GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET, BY DISTRIBUTION CHANNEL

19.1 OVERVIEW

19.2 DIRECT TENDER

19.2.1 HOSPITAL PHARMACY

19.2.2 ONLINE PHARMACY

19.2.3 RETAIL PHARMACY

19.3 OTHERS

20 GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET, SWOT AND DBMR ANALYSIS

21 GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET, COMPANY LANDSCAPE

21.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

21.2 COMPANY SHARE ANALYSIS: EUROPE

21.3 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

21.4 MERGERS & ACQUISITIONS

21.5 NEW PRODUCT DEVELOPMENT & APPROVALS

21.6 EXPANSIONS

21.7 REGULATORY CHANGES

21.8 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

22 GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET, BY GEOGRAPHY

22.1 GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

22.2 NORTH AMERICA

22.2.1 U.S.

22.2.1.1. U.S. CHRONIC KIDNEY DISEASE (CKD) MARKET, BY DIAGNOSIS AND TREATMENT

22.2.1.2. U.S. CHRONIC KIDNEY DISEASE (CKD) MARKET, BY STAGE

22.2.1.3. U.S. CHRONIC KIDNEY DISEASE (CKD) MARKET, BY AGE GROUP

22.2.1.4. U.S. CHRONIC KIDNEY DISEASE (CKD) MARKET, BY GENDER

22.2.1.5. U.S. CHRONIC KIDNEY DISEASE (CKD) MARKET, BY END USER

22.2.1.6. U.S. CHRONIC KIDNEY DISEASE (CKD) MARKET, BY DISTRUBUTION CHANNEL

22.2.2 CANADA

22.2.3 MEXICO

22.3 EUROPE

22.3.1 GERMANY

22.3.2 FRANCE

22.3.3 U.K.

22.3.4 HUNGARY

22.3.5 LITHUANIA

22.3.6 AUSTRIA

22.3.7 IRELAND

22.3.8 NORWAY

22.3.9 POLAND

22.3.10 ITALY

22.3.11 SPAIN

22.3.12 RUSSIA

22.3.13 TURKEY

22.3.14 NETHERLANDS

22.3.15 SWITZERLAND

22.3.16 REST OF EUROPE

22.4 ASIA-PACIFIC

22.4.1 JAPAN

22.4.2 CHINA

22.4.3 SOUTH KOREA

22.4.4 INDIA

22.4.5 AUSTRALIA

22.4.6 SINGAPORE

22.4.7 THAILAND

22.4.8 MALAYSIA

22.4.9 INDONESIA

22.4.10 PHILIPPINES

22.4.11 VIETNAM

22.4.12 REST OF ASIA-PACIFIC

22.5 SOUTH AMERICA

22.5.1 BRAZIL

22.5.2 ARGENTINA

22.5.3 PERU

22.5.4 COLOMBIA

22.5.5 VENEZUELA

22.5.6 REST OF SOUTH AMERICA

22.6 MIDDLE EAST AND AFRICA

22.6.1 SOUTH AFRICA

22.6.2 SAUDI ARABIA

22.6.3 UAE

22.6.4 EGYPT

22.6.5 KUWAIT

22.6.6 ISRAEL

22.6.7 REST OF MIDDLE EAST AND AFRICA

22.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

23 GLOBAL CHRONIC KIDNEY DISEASE (CKD) MARKET, COMPANY PROFILE

23.1 PFIZER INC.

23.1.1 COMPANY OVERVIEW

23.1.2 REVENUE ANALYSIS

23.1.3 GEOGRAPHIC PRESENCE

23.1.4 PRODUCT PORTFOLIO

23.1.5 RECENT DEVELOPMENTS

23.2 AMGEN INC.

23.2.1 COMPANY OVERVIEW

23.2.2 REVENUE ANALYSIS

23.2.3 GEOGRAPHIC PRESENCE

23.2.4 PRODUCT PORTFOLIO

23.2.5 RECENT DEVELOPMENTS

23.3 F. HOFFMANN-LA ROCHE LTD.

23.3.1 COMPANY OVERVIEW

23.3.2 REVENUE ANALYSIS

23.3.3 GEOGRAPHIC PRESENCE

23.3.4 PRODUCT PORTFOLIO

23.3.5 RECENT DEVELOPMENTS

23.4 ABBOTT.

23.4.1 COMPANY OVERVIEW

23.4.2 REVENUE ANALYSIS

23.4.3 GEOGRAPHIC PRESENCE

23.4.4 PRODUCT PORTFOLIO

23.4.5 RECENT DEVELOPMENTS

23.5 BRISTOL-MYERS SQUIBB COMPANY

23.5.1 COMPANY OVERVIEW

23.5.2 REVENUE ANALYSIS

23.5.3 GEOGRAPHIC PRESENCE

23.5.4 PRODUCT PORTFOLIO

23.5.5 RECENT DEVELOPMENTS

23.6 GSK PLC.

23.6.1 COMPANY OVERVIEW

23.6.2 REVENUE ANALYSIS

23.6.3 GEOGRAPHIC PRESENCE

23.6.4 PRODUCT PORTFOLIO

23.6.5 RECENT DEVELOPMENTS

23.7 FRESENIUS MEDICAL CARE

23.7.1 COMPANY OVERVIEW

23.7.2 REVENUE ANALYSIS

23.7.3 GEOGRAPHIC PRESENCE

23.7.4 PRODUCT PORTFOLIO

23.7.5 RECENT DEVELOPMENTS

23.8 KISSEI PHARMACEUTICAL CO., LTD.

23.8.1 COMPANY OVERVIEW

23.8.2 REVENUE ANALYSIS

23.8.3 GEOGRAPHIC PRESENCE

23.8.4 PRODUCT PORTFOLIO

23.8.5 RECENT DEVELOPMENTS

23.9 ASTRAZENECA

23.9.1 COMPANY OVERVIEW

23.9.2 REVENUE ANALYSIS

23.9.3 GEOGRAPHIC PRESENCE

23.9.4 PRODUCT PORTFOLIO

23.9.5 RECENT DEVELOPMENTS

23.1 MERCK & CO., INC.

23.10.1 COMPANY OVERVIEW

23.10.2 REVENUE ANALYSIS

23.10.3 GEOGRAPHIC PRESENCE

23.10.4 PRODUCT PORTFOLIO

23.10.5 RECENT DEVELOPMENTS

23.11 OTSUKA PHARMACEUTICAL CO., LTD.

23.11.1 COMPANY OVERVIEW

23.11.2 REVENUE ANALYSIS

23.11.3 GEOGRAPHIC PRESENCE

23.11.4 PRODUCT PORTFOLIO

23.11.5 RECENT DEVELOPMENTS

23.12 JOHNSON & JOHNSON

23.12.1 COMPANY OVERVIEW

23.12.2 REVENUE ANALYSIS

23.12.3 GEOGRAPHIC PRESENCE

23.12.4 PRODUCT PORTFOLIO

23.12.5 RECENT DEVELOPMENTS

23.13 FIBROGEN, INC.

23.13.1 COMPANY OVERVIEW

23.13.2 REVENUE ANALYSIS

23.13.3 GEOGRAPHIC PRESENCE

23.13.4 PRODUCT PORTFOLIO

23.13.5 RECENT DEVELOPMENTS

23.14 SIEMENS HEALTHCARE PRIVATE LIMITED

23.14.1 COMPANY OVERVIEW

23.14.2 REVENUE ANALYSIS

23.14.3 GEOGRAPHIC PRESENCE

23.14.4 PRODUCT PORTFOLIO

23.14.5 RECENT DEVELOPMENTS

23.15 NOVA BIOMEDICAL

23.15.1 COMPANY OVERVIEW

23.15.2 REVENUE ANALYSIS

23.15.3 GEOGRAPHIC PRESENCE

23.15.4 PRODUCT PORTFOLIO

23.15.5 RECENT DEVELOPMENTS

23.16 LUPIN

23.16.1 COMPANY OVERVIEW

23.16.2 REVENUE ANALYSIS

23.16.3 GEOGRAPHIC PRESENCE

23.16.4 PRODUCT PORTFOLIO

23.16.5 RECENT DEVELOPMENTS

23.17 ZYDUS GROUP

23.17.1 COMPANY OVERVIEW

23.17.2 REVENUE ANALYSIS

23.17.3 GEOGRAPHIC PRESENCE

23.17.4 PRODUCT PORTFOLIO

23.17.5 RECENT DEVELOPMENTS

23.18 BAYER AG

23.18.1 COMPANY OVERVIEW

23.18.2 REVENUE ANALYSIS

23.18.3 GEOGRAPHIC PRESENCE

23.18.4 PRODUCT PORTFOLIO

23.18.5 RECENT DEVELOPMENTS

23.19 AKEBIA THERAPEUTICS, INC.

23.19.1 COMPANY OVERVIEW

23.19.2 REVENUE ANALYSIS

23.19.3 GEOGRAPHIC PRESENCE

23.19.4 PRODUCT PORTFOLIO

23.19.5 RECENT DEVELOPMENTS

23.2 CSL VIFOR

23.20.1 COMPANY OVERVIEW

23.20.2 REVENUE ANALYSIS

23.20.3 GEOGRAPHIC PRESENCE

23.20.4 PRODUCT PORTFOLIO

23.20.5 RECENT DEVELOPMENTS

23.21 NOVARTIS

23.21.1 COMPANY OVERVIEW

23.21.2 REVENUE ANALYSIS

23.21.3 GEOGRAPHIC PRESENCE

23.21.4 PRODUCT PORTFOLIO

23.21.5 RECENT DEVELOPMENTS

23.22 SANOFI

23.22.1 COMPANY OVERVIEW

23.22.2 REVENUE ANALYSIS

23.22.3 GEOGRAPHIC PRESENCE

23.22.4 PRODUCT PORTFOLIO

23.22.5 RECENT DEVELOPMENTS

23.23 REATA PHARMACEUTICALS

23.23.1 COMPANY OVERVIEW

23.23.2 REVENUE ANALYSIS

23.23.3 GEOGRAPHIC PRESENCE

23.23.4 PRODUCT PORTFOLIO

23.23.5 RECENT DEVELOPMENTS

23.24 TRICIDA, INC.

23.24.1 COMPANY OVERVIEW

23.24.2 REVENUE ANALYSIS

23.24.3 GEOGRAPHIC PRESENCE

23.24.4 PRODUCT PORTFOLIO

23.24.5 RECENT DEVELOPMENTS

23.25 BOEHRINGER INGELHEIM INTERNATIONAL GMBH.

23.25.1 COMPANY OVERVIEW

23.25.2 REVENUE ANALYSIS

23.25.3 GEOGRAPHIC PRESENCE

23.25.4 PRODUCT PORTFOLIO

23.25.5 RECENT DEVELOPMENTS

23.26 ARDELYX

23.26.1 COMPANY OVERVIEW

23.26.2 REVENUE ANALYSIS

23.26.3 GEOGRAPHIC PRESENCE

23.26.4 PRODUCT PORTFOLIO

23.26.5 RECENT DEVELOPMENTS

23.27 CARA THERAPEUTICS.

23.27.1 COMPANY OVERVIEW

23.27.2 REVENUE ANALYSIS

23.27.3 GEOGRAPHIC PRESENCE

23.27.4 PRODUCT PORTFOLIO

23.27.5 RECENT DEVELOPMENTS

23.28 CALLIDITAS THERAPEUTICS AB.

23.28.1 COMPANY OVERVIEW

23.28.2 REVENUE ANALYSIS

23.28.3 GEOGRAPHIC PRESENCE

23.28.4 PRODUCT PORTFOLIO

23.28.5 RECENT DEVELOPMENTS

23.29 TRAVERE THERAPEUTICS

23.29.1 COMPANY OVERVIEW

23.29.2 REVENUE ANALYSIS

23.29.3 GEOGRAPHIC PRESENCE

23.29.4 PRODUCT PORTFOLIO

23.29.5 RECENT DEVELOPMENTS

23.3 OMEROS CORPORATION

23.30.1 COMPANY OVERVIEW

23.30.2 REVENUE ANALYSIS

23.30.3 GEOGRAPHIC PRESENCE

23.30.4 PRODUCT PORTFOLIO

23.30.5 RECENT DEVELOPMENTS

24 RELATED REPORTS

25 CONCLUSION

26 QUESTIONNAIRE

27 ABOUT DATA BRIDGE MARKET RESEARCH